Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ...

Elrexfio showed higher response rates but shorter PFS compared to Tecvayli in real-world settings for relapsed/refractory ...

One of biggest stories or developments in acute myeloid leukemia or AML is the wider adoption and use of the regimen of ...

Nearly 30% of families with children undergoing ALL treatment face catastrophic financial toxicity, including household ...

From left: Oya Gilbert, Bill Potts, Dr. Faseeh Khaja's nominator, Mayra, and Joe McDonough at the first annual Blood Cancer ...

Emotional readiness often lags behind intellectual awareness, leaving individuals unprepared for a cancer diagnosis. Support ...

Vaccines are particularly exciting because they can train the immune system to seek out and destroy these microscopic cancer ...